Amneal Pharmaceuticals has announced plans to build two new manufacturing facilities in Ahmedabad, India, with an investment of between $150 million and $200 million over the next four to five years. These facilities will focus on peptide synthesis and advanced sterile fill-finish manufacturing, strengthening the company’s presence in the country, where it has operated since 2008.
Founded in 2002 by Chirag and Chintu Patel, Amneal has a global manufacturing footprint with operations in the U.S., India, and Ireland. The company currently operates eight manufacturing sites in India, located in Ahmedabad, Dahej, Hyderabad, and Vizag, along with commercial offices in Mumbai. The new facilities will complement these existing sites and enhance the company’s capacity for developing next-generation medicines.
Amneal’s investment is aimed at expanding its capabilities in producing treatments for metabolic diseases and obesity, including GLP-1 and amylin receptor agonists, in collaboration with Metsera. The company’s existing Indian facilities have significant production capacity, manufacturing approximately 60 million units of injectables and 8.5 billion tablets annually.
The company has invested around $600 million in India over the past decade, including capital investments, acquisitions, and research and development. Amneal employs over 5,500 people across its Indian operations, with the new facilities expected to generate additional jobs in advanced manufacturing and R&D.
Amneal has also expanded its pharmaceutical portfolio in India in recent years, covering areas such as hospital critical care, ophthalmology, neurology, oncology, and diagnostics. The company continues to focus on developing a range of medicines tailored to the Indian market.